JP2023539871A5 - - Google Patents
Info
- Publication number
- JP2023539871A5 JP2023539871A5 JP2023513567A JP2023513567A JP2023539871A5 JP 2023539871 A5 JP2023539871 A5 JP 2023539871A5 JP 2023513567 A JP2023513567 A JP 2023513567A JP 2023513567 A JP2023513567 A JP 2023513567A JP 2023539871 A5 JP2023539871 A5 JP 2023539871A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cells
- amino acid
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070550P | 2020-08-26 | 2020-08-26 | |
| US63/070,550 | 2020-08-26 | ||
| US202163171187P | 2021-04-06 | 2021-04-06 | |
| US63/171,187 | 2021-04-06 | ||
| US202163218761P | 2021-07-06 | 2021-07-06 | |
| US63/218,761 | 2021-07-06 | ||
| PCT/US2021/047604 WO2022046938A1 (en) | 2020-08-26 | 2021-08-25 | Methods and compositions for treating glioblastoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539871A JP2023539871A (ja) | 2023-09-20 |
| JP2023539871A5 true JP2023539871A5 (enExample) | 2024-08-27 |
Family
ID=80352963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513567A Pending JP2023539871A (ja) | 2020-08-26 | 2021-08-25 | グリア芽細胞腫を処置するための方法および組成物 |
| JP2023513564A Pending JP2023539870A (ja) | 2020-08-26 | 2021-08-25 | グリア芽細胞腫を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513564A Pending JP2023539870A (ja) | 2020-08-26 | 2021-08-25 | グリア芽細胞腫を処置するための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20230364139A1 (enExample) |
| EP (2) | EP4204443A4 (enExample) |
| JP (2) | JP2023539871A (enExample) |
| CN (2) | CN116348482A (enExample) |
| CA (2) | CA3193009A1 (enExample) |
| WO (2) | WO2022046938A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| US12378297B2 (en) | 2017-04-14 | 2025-08-05 | The General Hospital Corporation | Chimeric antigen receptor T cells targeting the tumor microenvironment |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| JP2023539871A (ja) * | 2020-08-26 | 2023-09-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グリア芽細胞腫を処置するための方法および組成物 |
| CN116555204B (zh) * | 2023-07-04 | 2023-09-12 | 苏州驾玉生物医药有限公司 | 一种性能提升的突变荧光素酶及其应用 |
| WO2025096603A1 (en) * | 2023-10-30 | 2025-05-08 | City Of Hope | Targeted chimeric antigen receptor modified t cells for treatment of il13ralpha2 positive malignancies |
| WO2025193475A1 (en) * | 2024-03-14 | 2025-09-18 | The Regents Of The University Of California | Enhancing immune cell innate and adaptive responses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884603B2 (en) * | 1998-04-03 | 2005-04-26 | The Penn State Research Foundation | Nucleic acids encoding IL13 mutants |
| EP2331566B1 (en) * | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| JP2017537622A (ja) * | 2014-12-02 | 2017-12-21 | ロジャー・ウィリアムズ・ホスピタル | がんを治療するための方法及び組成物 |
| JP6821688B2 (ja) * | 2015-10-09 | 2021-01-27 | ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | キメラ抗原受容体および使用方法 |
| PL3368571T3 (pl) * | 2015-10-30 | 2023-05-02 | The Regents Of The University Of California | Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| US20180100016A1 (en) * | 2016-12-22 | 2018-04-12 | Xiaotong Song | Use of car-modified human natural killer cells to treat cancer |
| BR112019017256A2 (pt) * | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics Inc | proteínas de ligação gd2, nkg2d e cd16 |
| CA3095757A1 (en) * | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| JP2023539871A (ja) * | 2020-08-26 | 2023-09-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グリア芽細胞腫を処置するための方法および組成物 |
-
2021
- 2021-08-25 JP JP2023513567A patent/JP2023539871A/ja active Pending
- 2021-08-25 US US18/042,989 patent/US20230364139A1/en active Pending
- 2021-08-25 CA CA3193009A patent/CA3193009A1/en active Pending
- 2021-08-25 CA CA3193006A patent/CA3193006A1/en active Pending
- 2021-08-25 EP EP21862677.8A patent/EP4204443A4/en active Pending
- 2021-08-25 WO PCT/US2021/047604 patent/WO2022046938A1/en not_active Ceased
- 2021-08-25 WO PCT/US2021/047600 patent/WO2022046935A2/en not_active Ceased
- 2021-08-25 CN CN202180072324.4A patent/CN116348482A/zh active Pending
- 2021-08-25 US US18/042,985 patent/US20230322894A1/en active Pending
- 2021-08-25 EP EP21862676.0A patent/EP4203990A4/en active Pending
- 2021-08-25 CN CN202180072297.0A patent/CN116528889A/zh active Pending
- 2021-08-25 JP JP2023513564A patent/JP2023539870A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539871A5 (enExample) | ||
| JP2023539870A5 (enExample) | ||
| RU2685479C2 (ru) | Химерный антигенный рецептор | |
| JP6285553B2 (ja) | 抗ｃｄ３０キメラ抗原受容体およびその使用 | |
| JP6971986B2 (ja) | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 | |
| JP2023534928A (ja) | 改変免疫細胞及びその使用 | |
| JPWO2020017479A1 (ja) | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ | |
| JP2022513148A (ja) | Ｔ細胞の改変 | |
| AU2008303453B2 (en) | An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
| WO2019096115A1 (zh) | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 | |
| CN113896801B (zh) | 靶向人Claudin18.2和NKG2DL的嵌合抗原受体细胞及其制备方法和应用 | |
| US20230398216A1 (en) | Chimeric activation receptors | |
| JP2023524873A (ja) | 方法 | |
| US20230030680A1 (en) | Chimeric gmcsf-il18 receptor | |
| CN114457117A (zh) | 树突细胞肿瘤疫苗和其用途 | |
| JP7748934B2 (ja) | ユニバーサルｃａｒ－ｔ細胞ならびにその調製および用途 | |
| Shin et al. | Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| CN113549157A (zh) | 双靶向嵌合抗原受体及其应用 | |
| KR20220038776A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| EP4061385A1 (en) | A method for redesign and expansion of nk92 cells for use in immunotherapy | |
| WO2021115333A1 (zh) | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 | |
| CN115786268A (zh) | 工程化免疫细胞及其用途 | |
| US20240148867A1 (en) | Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine |